[HTML] frontiersin.org

[HTML][HTML] Effects of oral anticoagulant therapy in patients with pulmonary diseases

J Lai, S Feng, S Xu, X Liu - Frontiers in Cardiovascular Medicine, 2022 - frontiersin.org
Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …
被引用次数：5 相关文章

Effects of oral anticoagulant therapy in patients with pulmonary diseases.

J Lai, S Feng, S Xu, X Liu - Frontiers in Cardiovascular Medicine, 2022 - europepmc.org
Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …
[HTML] nih.gov

[HTML][HTML] Effects of oral anticoagulant therapy in patients with pulmonary diseases

J Lai, S Feng, S Xu, X Liu - Frontiers in Cardiovascular Medicine, 2022 - ncbi.nlm.nih.gov
Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …

Effects of oral anticoagulant therapy in patients with pulmonary diseases

J Lai, S Feng, S Xu, X Liu - Frontiers in cardiovascular …, 2022 - pubmed.ncbi.nlm.nih.gov
Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …

Effects of oral anticoagulant therapy in patients with pulmonary diseases.

J Lai, S Feng, S Xu, X Liu - Frontiers in Cardiovascular Medicine, 2022 - europepmc.org
Background To evaluate the effect of oral anticoagulants (OACs) therapy, including vitamin
K antagonist (VKA) and direct oral anticoagulants (DOAC) in patients with pulmonary …